BACKGROUND: The FDA’s modified risk authorization for IQOS® is contingent upon approved post-market surveillance studies. Cross-Sectional Post-Market Adult Consumer Study (hereinafter termed CS PACS) and the Longitudinal Cohort LC are contiguous surveys designed to fulfill this proviso. OBJECTIVES: PACS seeks assess tobacco use patterns in users, perceptions of IQOS®, transition cessation behav...